Vanda Pharmaceuticals Inc. expanded its Board of Directors from six to seven members. Dr. Charles C. Duncan, Ph.D., was appointed as an independent director effective April 22, 2026. Dr. Duncan brings extensive experience from his three-decade career as a sell-side biotechnology equity research analyst. The appointment includes a compensation package consisting of an initial $390,000 restricted stock unit (RSU) award and a $50,000 annual cash fee. Dr. Duncan is eligible for annual RSU grants valued at $260,000 starting in 2026.